Analyst Michael Ulz from Morgan Stanley maintained a Hold rating on Sarepta Therapeutics and keeping the price target at $20.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Michael Ulz’s rating is based on several considerations surrounding the recent updates to Sarepta Therapeutics’ Elevidys label. The addition of a black box warning for acute liver injury and acute liver failure has raised concerns about patient safety, prompting Sarepta to collaborate with the FDA to enhance prescriber guidelines and monitoring protocols. These changes, including the removal of the non-ambulatory indication, suggest a cautious approach as the company plans further studies to address these risks.
Moreover, the updated label introduces new warnings about the increased risk of serious infections due to immunosuppression, which could impact the drug’s market performance. While these updates align with management’s previous guidance, they underscore the challenges Sarepta faces in maintaining patient access and driving sales for Elevidys. As a result, Michael Ulz has opted for a Hold rating, reflecting a balanced view of the potential risks and opportunities associated with the stock.
In another report released on November 7, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $17.00 price target.
SRPT’s price has also changed dramatically for the past six months – from $35.740 to $18.810, which is a -47.37% drop .